drugset / Trial / NCT01413542

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542

Completed 44 enrolled Vanderbilt University
RandomizedCrossoverDouble-blindTreatment

Summary

The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.

Timeline

Start
2011-11
Primary completion
2013-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bradykinin Protein / enzyme biologic 23.6 unknown Other
Comparator Bradykinin Protein / enzyme biologic 47.2 unknown Other
Comparator Bradykinin Protein / enzyme biologic 94.3 unknown Other
Comparator ENALAPRILAT ANHYDROUS Small molecule 0.33 ug Other
Comparator GLP-1 Peptide 0.45 unknown Other
Comparator GLP-1 Peptide 3.6 unknown Other
Comparator Sitagliptin Small molecule 200 mg Oral
Comparator Substance P Small molecule 2 unknown Other
Comparator Substance P Small molecule 4 unknown Other
Comparator Substance P Small molecule 8 unknown Other
Comparator brain natriuretic peptide Peptide 0.9 unknown Other
Comparator brain natriuretic peptide Peptide 1.8 unknown Other
Comparator brain natriuretic peptide Peptide 3.6 unknown Other